ESO Conference 2015 • Scottish Exhibition and Conference Centre • Glasgow, UK • April 17-19, 2015 Official Satellite Symposium of the European Stroke Conference: Advances in Clinical and Preclinical Research with Cerebrolysin New Data & New Insights Friday, 17 April 2015 12:30 – 14:00 Room: Boisdale Hall ABBREVIATED PRESCRIBING INFORMATION: Name of the medicinal product: Cerebrolysin® - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin® concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer’s type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. Reference SPC – CCDS Version 1.0 (Jan 28 2014) CERE/A/03/2015/6 ESO Conference 2015 Scottish Exhibition and Conference Centre Glasgow, UK April 17-19, 2015 Programme of Symposium: Chairmen: Marc Fisher, USA; Wolf-Dieter Heiss, Germany Advances in Pre-Clinical Stroke Research – The new Cerebrolysin Dose-Response Study Michael Chopp, USA The CREGS-S Trial - Combining Rigorous Evaluation with Real-life Studies Martin Dichgans, Germany The Effects of Cerebrolysin in Stroke Rehabilitation – The E-Compass Trial Results Yun Hee Kim, Korea The effects of Cerebrolysin in Stroke Rehabilitation – The CARS-Trial Results Dafin Muresanu, Romania Date: Friday, 17 April 2015 12:30 – 14:00 Room: Boisdale Hall Get a free copy! Please visit our booth (#3) to register for this symposium. As registered participant you’ll receive a copy of the book “Stroke - Practical Guide for Clinicians” (Editor: Natan M. Bornstein) for free after the symposium. (limited - while stock lasts) www.everpharma.com